Background The efficacy, safety and immunogenicity risk of switching between an originator
biologic and a biosimilar or from one biosimilar to another are of potential concern …

Biological medicines have improved patients' outcomes, but their high costs may limit
access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality …

To date, no consensus exists among stakeholders about switching patients between
reference biological products (RPs) and biosimilars, which may have been curbing the …

Background Multiple switches (transitions) between biosimilars of the same reference
biologic are now a reality, and they are expected to become more common in the future as …

Methods A systematic search was conducted using the Medline® and Embase® databases
up to 30 June 2017 employing specific medical subject heading terms. Additionally, the …

Biosimilars are increasingly available for the treatment of many serious disorders, however
some concerns persist about switching a patient to a biosimilar whose condition is stable …

With the increasing availability of biosimilars, the practice of switching therapies for non-
medical reasons between an originator biologic and an analogous biosimilar has become …

Many of the best-selling 'blockbuster'biological medicinal products are, or will soon be,
facing competition from similar biological medicinal products (biosimilars) in the EU …

Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well-
accepted practice, switching clinically stable patients from an originator to a biosimilar is an …

Highlights•There are different regulatory approaches toward interchanging
biosimilars.•Blinded clinical studies do not reflect switching in clinical practice.•Current data …